Navigation Links
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Date:9/18/2007

ek primary analysis from ARTEMIS will be submitted to the FDA later this year as part of the post-marketing commitment for PREZISTA.

PREZISTA, co-administered with 100 mg ritonavir and with other antiretroviral agents, is currently indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor.

This indication is based on week 24 analyses of plasma HIV RNA levels and CD4+ cell counts from two controlled trials of PREZISTA/r in combination with other antiretroviral drugs. Both studies were conducted in clinically advanced, treatment-experienced (NRTIs, NNRTIs, and PIs) adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

The following points should be considered when initiating therapy with PREZISTA/r:

-- Treatment history and, when available, genotypic or phenotypic testing

should guide the use of PREZISTA/r.

-- The use of other active agents with PREZISTA/r is associated with a

greater likelihood of treatment response.

-- The risks and benefits of PREZISTA/r have not been established in

treatment-naive adult patients or pediatric patients.

PREZISTA received accelerated approval in June 2006 based on the 24-week analysis of HIV viral load and CD4+ cell counts from the pooled analysis of the TMC114-C213 (POWER 1) and TMC114-C202 (POWER 2) Phase 2b studies. As part of the post-marketing commitment, 48-week data from ongoing Phase 3 studies, including ARTEMIS, and 96-week data from POWER 1, 2, and 3 will be required before the FDA can consider traditional approval for PREZISTA.

About the ARTEMIS study

ARTEMIS is an international ongoing, randomized, open-label Phase 3 trial in which 689 treatment-naive adult patients were treated. The participants enrolled in the study had not previously received treatment w
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014   TRU-D SmartUVC LLC, producers ... robot, announced today that the General Services Administration has ... 2019.   This newly formed agreement will ... of government purchasers, including Department of Veteran Affairs and ... Security contacts purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)... , Dec. 22, 2014 Cyberonics, Inc. (NASDAQ: ... the treatment and management of epilepsy, today announced it will ... Conference on Wednesday, January 14, 2015, in San ... President and Chief Executive Officer, will speak at 11:00 AM ... be accessed by clicking on the Investor Relations link on ...
(Date:12/22/2014)... Dec. 22, 2014  Mark Farrah Associates (MFA), ... a summary of the 2015 marketplace exchange projections ... According to a recent ASPE ... Evaluation, Department of Health and Human Services) report, ... individual medical plans through the Marketplace as of ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2Insights into the Marketplace and Individual Market Growth 2
... /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: KH ) ... marketer of orthopedic implants in China, today announced that the ... August 16, 2011, before the market opens. Kanghui ... August 16, 2011 to discuss second quarter results and answer ...
... ATLANTA, July 28, 2011 Data presented this week at ... many people have low vitamin D levels and that testing ... to published data from the Third National Health and Nutrition ... only 23 percent of Americans have vitamin D levels over ...
Cached Medicine Technology:China Kanghui Holdings to Report Second Quarter 2011 Financial Results on August 16, 2011 2Data Presented at American Association for Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels 2Data Presented at American Association for Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels 3
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... December 25, 2014 The short film “Color ... created in honor of a true 9/11 hero, Welles Remy ... festivals including the 24 hours of Nuremberg International Short Film ... , Actress, screenwriter and director Luciana Lagana ... film together with her husband, Gregory Graham - ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... illnesses can receive effective, less expensive care from a clinic ... a team of dedicated health care professionals, a new study ... and need either hospitalization or a trip to the emergency ... clinic at the University of Texas in Houston versus usual ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... , SOUTH SAN FRANCISCO, Calif., July 10 ... the International Society on Thrombosis and Haemostasis (ISTH) XII ... drug elinogrel, a P2Y(12) ADP receptor antagonist currently in ... inhibitor anticoagulant antidote in pre-clinical development, as well as ...
... adulthood, study shows , THURSDAY, July 9 (HealthDay News) ... can persist into adulthood, U.S. researchers report. , Young ... than 5.5 pounds at birth) have an increased risk ... findings suggest that not only are [low birth weight] ...
... ... are now available in Canada from Electro Sonic. , ... Chatsworth, CA (PRWEB) July 10, 2009 -- NMB Technologies Corporation, a ... have reached a distribution agreement. Under the terms of this agreement, Electro Sonic, ...
... 10 Eli Lilly and Company (NYSE: ... 35th year of support for the Indiana Black Expo (IBE) Summer Celebration, ... presence at the IN Shape Indiana Black and Minority ... in these uncertain economic times. , , An example of this ...
... Growing in the number of those afflicted, Alzheimer,s takes ... caregivers, "Alzheimer,s Days Gone By: For Those Caring For Their ... Lueckenotte weaves a heartfelt mix of personal experience and sound ... of loved ones during the descent into dementia. , ...
... (Nasdaq: QGLY ) , ... Rosenbloom has resumed providing services to the Company,s Quigley Pharma subsidiary. ... late May, 2009. , , Ted Karkus, Chairman and interim ... Rosenbloom again serving our Pharma subsidiary and helping in the development ...
Cached Medicine News:Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 2Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 3Health News:Respiratory Issues Linger for Smallest Babies 2Health News:NMB Expands in Canada 2Health News:Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 2Health News:Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 3Health News:Insightful Handbook for Alzheimer's Caregivers 2Health News:Insightful Handbook for Alzheimer's Caregivers 3Health News:Dr. Richard Rosenbloom Resumes Services To The Quigley Corporation's Pharma Subsidiary 2Health News:Dr. Richard Rosenbloom Resumes Services To The Quigley Corporation's Pharma Subsidiary 3
Curved delicate 5 mm blades....
Yasargil clip applying forceps Mini. Stainless steel jaw....
... Micro tissue forceps ... handles, soft spring tension ... anodized round handles, extremely ... easy to handle, fatigueless ...
Micro suture forceps....
Medicine Products: